BCAB — BioAtla, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1826892 ·
Last close
$3.91
Market Cap
$6.48M
52W High
$13.25
52W Low
$3.26
ADV30
34,675
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -9,308,000 | -6,344,000 | 8,566,000 | 1,961,000 | 45,875,000 |
| Dec 2025 | 2,000,000 | — | -9,255,000 | -9,784,000 | 13,828,000 | 7,118,000 | 50,017,000 |
| Sep 2025 | 0 | — | -13,789,000 | -15,778,000 | 15,908,000 | 8,320,000 | 47,145,000 |
| Jun 2025 | 0 | — | -18,647,000 | -18,711,000 | 27,129,000 | 18,207,000 | 43,874,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-48,204,000
Investing CF
$0
Financing CF
$6,276,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-50.50
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-545,646,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-59,305,000
Pretax Income TTM
$-59,607,000
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$2,000,000
EBITDA
$-50,089,000
Free Cash Flow
$-18,032,376
Enterprise Value
$10,247,057
Total Cash
$1,961,000
Total Debt
$6,094,000
Shares Out
1,656,926
Trailing EPS
$-41.56
Book Value
$-22.48
ROE
—
ROA
-134.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,000,000 | -59,305,000 | -59,607,000 | 13,828,000 | 50,017,000 | — | -48,204,000 |
| Dec 2024 | 11,000,000 | -73,943,000 | -69,776,000 | 52,422,000 | 38,157,000 | — | -71,936,000 |
| Dec 2023 | 0 | -129,687,000 | -123,462,000 | 119,658,000 | 48,986,000 | — | -104,015,000 |
| Dec 2022 | 0 | -108,140,000 | -106,482,000 | 225,736,000 | 45,397,000 | — | -90,420,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.34
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BCLI | BRAINSTORM CELL THERAPEUTICS INC. | $6.95M | $0.63 | — |
| LIMN | Liminatus Pharma, Inc. | $7.36M | $0.16 | — |
| CPMV | Mosaic ImmunoEngineering Inc. | $5.03M | $0.69 | — |
| PMCB | PharmaCyte Biotech, Inc. | $8.43M | $0.79 | — |
| CELZ | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. | $8.65M | $2.34 | — |
News headlines (Yahoo Finance, 1h cache)
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
2026-05-18 10:45 · Yahoo
BioAtla Announces Share Consolidation
2026-03-31 20:06 · Yahoo
BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
2026-03-31 20:05 · Yahoo
BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets
2026-03-02 12:30 · Yahoo
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma
2025-12-31 12:00 · Yahoo
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing
2025-11-21 05:25 · Yahoo
BioAtla Inc (BCAB) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Promising Trial ...
2025-11-14 05:04 · Yahoo
BioAtla (BCAB) Q3 2025 Earnings Call Transcript
2025-11-13 22:07 · Yahoo
BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
2025-11-13 21:05 · Yahoo
BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas
2025-11-07 14:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.